These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 31219910)
1. Bone Marrow Necrosis in a Patient Following Blinatumomab Therapy. Yarali N; Isik M; Arman-Bilir O; Guzelkucuk Z; Oguz-Erdogan AS J Pediatr Hematol Oncol; 2020 Apr; 42(3):e167-e169. PubMed ID: 31219910 [TBL] [Abstract][Full Text] [Related]
2. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. Viardot A; Locatelli F; Stieglmaier J; Zaman F; Jabbour E Ann Hematol; 2020 Oct; 99(10):2215-2229. PubMed ID: 32856140 [TBL] [Abstract][Full Text] [Related]
3. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment. Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia. Ribera JM Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835 [TBL] [Abstract][Full Text] [Related]
5. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. Topp MS; Kufer P; Gökbuget N; Goebeler M; Klinger M; Neumann S; Horst HA; Raff T; Viardot A; Schmid M; Stelljes M; Schaich M; Degenhard E; Köhne-Volland R; Brüggemann M; Ottmann O; Pfeifer H; Burmeister T; Nagorsen D; Schmidt M; Lutterbuese R; Reinhardt C; Baeuerle PA; Kneba M; Einsele H; Riethmüller G; Hoelzer D; Zugmaier G; Bargou RC J Clin Oncol; 2011 Jun; 29(18):2493-8. PubMed ID: 21576633 [TBL] [Abstract][Full Text] [Related]
6. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800 [TBL] [Abstract][Full Text] [Related]
7. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. Zugmaier G; Gökbuget N; Klinger M; Viardot A; Stelljes M; Neumann S; Horst HA; Marks R; Faul C; Diedrich H; Reichle A; Brüggemann M; Holland C; Schmidt M; Einsele H; Bargou RC; Topp MS Blood; 2015 Dec; 126(24):2578-84. PubMed ID: 26480933 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of blinatumomab: a real world data. Apel A; Ofran Y; Wolach O; Shimony S; Ram R; Levi I; Zektser M; Koren-Michowitz M Ann Hematol; 2020 Apr; 99(4):835-838. PubMed ID: 32076826 [TBL] [Abstract][Full Text] [Related]
10. Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab. Wilke AC; Gökbuget N Expert Opin Drug Saf; 2017 Oct; 16(10):1191-1202. PubMed ID: 28825327 [TBL] [Abstract][Full Text] [Related]